The basis of drug pricing in our country is a specific legal-technical mechanism. This is the so-called Positive Drug List (PDL). Its legal framework is provided in the Law on Medicinal Products in Human Medicine (Art. 262 et seq.) and further developed in the Ordinance on the Conditions, Rules, and Procedures for Regulating and Registering of Prices for Medicinal Products. The purpose of this article is to provide a more detailed look at this specific subject matter, while offering the author's interpretation of the legal characteristics, structure, and functions of the PDL.